Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

31.37 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
4 Healthcare Stocks With Massive Gains—and More to Come
Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year. 
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Economy Tariff
Royalty Pharma Announces Upcoming Investor Day
From Royalty Pharma plc
Via GlobeNewswire
3 Reasons to Sell RPRX and 1 Stock to Buy Instead
Over the past six months, Royalty Pharma has been a great trade. While the S&P 500 was flat, the stock price has climbed by 17.3% to $33.06 per share. This performance may have investors wondering how... 
Via StockStory
Topics Stocks
Exposures US Equities
Peering Into Royalty Pharma's Recent Short Interest
Via Benzinga
The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry
In this video lesson, I review the overall market and a new swing position for Monday's session. 
Via Talk Markets
Topics ETFs Stocks / Equities
Uncovering Noteworthy Technical Analysis Findings for ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX).
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout. 
Via Chartmill
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
3 Value Stocks in Hot Water
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
How Do Investors Really Feel About Royalty Pharma?
Via Benzinga
Is ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Ready to Break Out of Its Range?
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Based on good technical signals, ROYALTY PHARMA PLC- CL A is potentially setting up for a breakout. 
Via Chartmill
1 Stock Under $50 with Exciting Potential and 2 to Ignore
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma. 
Via Benzinga
Royalty Pharma Announces R&D Funding Collaboration With Biogen
Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus 
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $594 million. Its GAAP profit of $0.57 per share was... 
Via StockStory
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
U.S. 
Via Benzinga
Royalty Pharma Reports Q4 and Full Year 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Earnings Scheduled For February 11, 2025
Via Benzinga
Royalty Pharma Earnings: What To Look For From RPRX
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
From Royalty Pharma plc
Via GlobeNewswire
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United... 
Via Benzinga
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Via Benzinga
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
Jim Cramer Likes Walmart, Recommends Buying This 'Very, Very Good' Financial Stock
Jim Cramer likes Walmart (WMT). Walmart provides body cameras to employees in a pilot program. Cramer says Royalty Pharma (RPRX) is a disappointing stock. 
Via Benzinga
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.